No Data
No Data
Express News | Protagenic Therapeutics Successfully Concludes Third Cohort In Single Dose Portion Of Phase 1 Trial For Stress-Related Neuropsychiatric Disorders
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
Next clinical progress update expected in April 2024NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mis
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ETNEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Com
Express News | Protagenic Therapeutics Announces Resolution Of Nasdaq Deficiency Notice
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. , a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550 as the closing bid price of shares of PTIX
EYEN, BYSI and FENG Among Mid-day Movers
No Data